SUPRIYA LIFESCIENCE Financial Statement Analysis
|
||
|
The Revenues of SUPRIYA LIFESCIENCE have increased by 18.86% YoY .
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has increased by 11.26 % YoY. |
||
SUPRIYA LIFESCIENCE Last 5 Annual Financial Results
[BOM: 543434|NSE : SUPRIYA]
| Standalone | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹828 Cr | ₹696 Cr | ₹570 Cr | ₹461 Cr | ₹530 Cr |
| Expenses | ₹533 Cr | ₹436 Cr | ₹395 Cr | ₹332 Cr | ₹316 Cr |
| Operating Profit (Excl OI) | ₹295 Cr | ₹261 Cr | ₹176 Cr | ₹128 Cr | ₹214 Cr |
| Other Income | ₹11 Cr | ₹9.82 Cr | ₹11 Cr | ₹9.94 Cr | ₹7.58 Cr |
| Interest | ₹2.77 Cr | ₹1.81 Cr | ₹5.15 Cr | ₹3.08 Cr | ₹4.20 Cr |
| Depreciation | ₹28 Cr | ₹20 Cr | ₹16 Cr | ₹12 Cr | ₹10 Cr |
| Profit Before Tax | ₹275 Cr | ₹248 Cr | ₹166 Cr | ₹123 Cr | ₹207 Cr |
| Profit After Tax | ₹209 Cr | ₹188 Cr | ₹119 Cr | ₹90 Cr | ₹152 Cr |
| Earnings Per Share (Rs) | ₹25.98 | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| PAT Margin (%) | 22.86 | 24.04 | 18.41 | 17.40 | 25.80 |
| ROE(%) | 19.06 | 20.74 | 15.73 | 13.66 | 34.34 |
| ROCE(%) | 25.30 | 27.62 | 22.31 | 18.71 | 43.34 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
Key Financials |
||
| Market Cap | : | ₹ 5,134.3 Cr |
| Revenue (TTM) | : | ₹ 879.0 Cr |
| Net Profit(TTM) | : | ₹ 177.2 Cr |
| EPS (TTM) | : | ₹ 22.0 |
| P/E (TTM) | : | 29.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUPRIYA LIFESCIENCE | -26.6% | -26.6% | -18.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.9% | 7.8% | 13% |
| DIVIS LABORATORIES | 11.5% | 20.6% | 68% |
| TORRENT PHARMACEUTICALS | 1% | 1.8% | 34.3% |
| CIPLA | 1.1% | 7.9% | -6.3% |
| DR REDDYS LABORATORIES | 1.1% | 11.8% | 14.9% |
| MANKIND PHARMA | 5.7% | 10.8% | 15.2% |
| LUPIN | 1.7% | 3.9% | 2.9% |
| ZYDUS LIFESCIENCES | -0.5% | 4.5% | 29.6% |
SUPRIYA LIFESCIENCE Revenues
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 18.86 % |
| 5 Yr CAGR | 11.79 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹828 Cr | 18.86 | |
| Mar2025 | ₹696 Cr | 22.12 | |
| Mar2024 | ₹570 Cr | 23.73 | |
| Mar2023 | ₹461 Cr | -13.04 | |
| Mar2022 | ₹530 Cr | - | |
SUPRIYA LIFESCIENCE Operating Profit
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 13.04 % |
| 5 Yr CAGR | 8.35 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹295 Cr | 13.04 | |
| Mar2025 | ₹261 Cr | 48.51 | |
| Mar2024 | ₹176 Cr | 36.79 | |
| Mar2023 | ₹128 Cr | -39.98 | |
| Mar2022 | ₹214 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -4.89 % |
| 5 Yr CAGR | -3.07 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 35.63% | -4.89 | |
| Mar2025 | 37.46% | 21.58 | |
| Mar2024 | 30.81% | 10.55 | |
| Mar2023 | 27.87% | -30.96 | |
| Mar2022 | 40.37% | - | |
SUPRIYA LIFESCIENCE Profit After Tax
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 11.26 % |
| 5 Yr CAGR | 8.34 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹209 Cr | 11.26 | |
| Mar2025 | ₹188 Cr | 57.80 | |
| Mar2024 | ₹119 Cr | 32.56 | |
| Mar2023 | ₹90 Cr | -40.81 | |
| Mar2022 | ₹152 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -4.91 % |
| 5 Yr CAGR | -2.98 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 22.86 % | -4.91 | |
| Mar2025 | 24.04 % | 30.58 | |
| Mar2024 | 18.41 % | 5.80 | |
| Mar2023 | 17.4 % | -32.56 | |
| Mar2022 | 25.8 % | - | |
SUPRIYA LIFESCIENCE Earnings Per Share (EPS)
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 11.26 % |
| 5 Yr CAGR | 8.34 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹26 | 11.26 | |
| Mar2025 | ₹23 | 57.77 | |
| Mar2024 | ₹15 | 32.62 | |
| Mar2023 | ₹11 | -40.83 | |
| Mar2022 | ₹19 | - | |
SUPRIYA LIFESCIENCE Return on Capital Employed (ROCE)
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | -8.40 % |
| 5 Yr CAGR | -12.59 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 25.3% | -8.40 | |
| Mar2025 | 27.62% | 23.80 | |
| Mar2024 | 22.31% | 19.24 | |
| Mar2023 | 18.71% | -56.83 | |
| Mar2022 | 43.34% | - | |
SUPRIYA LIFESCIENCE Share Price vs Sensex
| Current Share Price | : | ₹637.8 |
| Current MarketCap | : | ₹ 5,134.3 Cr |
| Updated EOD on | : | Nov 11,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUPRIYA LIFESCIENCE | -26.6% |
-26.6% |
-18.9% |
| SENSEX | 5.9% |
13% |
-1.9% |
SUPRIYA LIFESCIENCE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | 4.3% | 8.1% | 0.6% |
| BSE HEALTHCARE | 3.7% | 8.5% | 18.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | 4.4% | 8.4% | 0.8% |
| NIFTY MICROCAP 250 | 3.2% | 0.4% | 7.4% |
| NIFTY SMALLCAP 500 | 2.5% | 1% | NA |
| NIFTY TOTAL MARKET MOMENTUM QUALITY 50 | 1.4% | 2.7% | 0.3% |
You may also like the below Video Courses
FAQ about SUPRIYA LIFESCIENCE Financials
How the annual revenues of SUPRIYA LIFESCIENCE have changed ?
The Revenues of SUPRIYA LIFESCIENCE have increased by 18.86% YoY .
How the Earnings per Share (EPS) of SUPRIYA LIFESCIENCE have changed?
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has increased by 11.26 % YoY .
Check out Intrinsic Value of Peers of SUPRIYA LIFESCIENCE
Compare Stock Analytics of Peers of SUPRIYA LIFESCIENCE
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
